

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

COVID-19 vaccinations in pregnancy and haematological malignancy patients, surgery after COVID-19, risk assessment of XBB.1.5

Peer reviewed journals featured

- Meta-analyses and systematic reviews on:
 - Neonatal outcomes of COVID-19 vaccination in pregnancy [here](#)
 - Immunogenicity and risks following SARS-CoV-2 vaccination and booster in hematologic malignancy patients [here](#)
- Randomised controlled trials on:
 - Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes [here](#) and associated commentary [here](#)
 - Efficacy of combined visual-olfactory training for patients with COVID-19 resultant olfactory loss [here](#) and associated commentary [here](#)
 - Long-term outcomes in critically ill patients with COVID-19 (REMAP-CAP trial) [here](#) and associated editorial [here](#)
 - Favipiravir in hospitalised patients (PIONEER trial) [here](#) and associated commentary [here](#)
 - VV116 versus nirmatrelvir–ritonavir for oral treatment of COVID-19 [here](#)
 - Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 [here](#)
- Observational studies on:
 - B and T-cell immune responses after booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies [here](#)
 - Association of time to surgery after COVID-19 infection with risk of postoperative cardiovascular morbidity [here](#)
 - Complications following elective major noncardiac surgery among patients with prior SARS-CoV-2 infection [here](#)
 - Association of COVID-19 vaccination with breakthrough infections and complications in patients with cancer [here](#)
 - Association of SARS-CoV-2 spike protein antibody vaccine response with infection severity in patients with cancer [here](#) and associated editorial [here](#)
 - Symptoms of pandemic-associated traumatic stress among mothers in the US [here](#)

- Association of COVID-19 vaccination rates of staff and COVID-19 illness and death among residents and staff in US nursing homes [here](#)
- Sociodemographic comparison of children with high-risk medical conditions referred versus identified through screening plus outreach for COVID-19 therapeutics [here](#)
- Analysis of rituximab use, timing and SARS-CoV-2 vaccination, and COVID-19 hospitalisation or death in patients with multiple sclerosis [here](#)
- Child mortality in England during the first 2 years of the COVID-19 pandemic [here](#)
- Complications, adverse events, high costs, and disparities in multisystem inflammatory syndrome in children vs COVID-19 [here](#) and associated commentary [here](#)
- Risks and burdens of incident dyslipidaemia in long COVID [here](#) and commentary [here](#)
- Comparison of rapid antigen tests between Delta and Omicron variants of SARS-CoV-2 [here](#)
- Direct and indirect effects of the COVID-19 pandemic on mortality in Switzerland [here](#)
- Early estimates of bivalent mRNA vaccine in preventing COVID-19 associated emergency department hospitalisations among immunocompetent adults [here](#) and adults ≥ 65 years [here](#)
- Effectiveness of COVID-19 vaccines in adolescents and children [here](#) and associated editorial [here](#)
- Commentary on:
 - Ecology of SARS-CoV-2 in the post-pandemic era [here](#)
 - The impact of ending 'zero COVID' in China [here](#)
 - Science and truth during the COVID-19 pandemic [here](#)

Letters and correspondence discussed

- Travel times to facilities offering oral medication therapy for COVID-19 [here](#)
- Omicron BQ.1 and BQ.1.1 escape neutralisation by breakthrough infection [here](#)
- Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB [here](#)
- Neutralisation against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster [here](#)

Pre-peer review articles featured

- Delta and Omicron transmission and vaccine impact in Australian educational settings [here](#)
- Effectiveness of COVID-19 vaccination in a regional population in Australia [here](#)
- Enhanced transmissibility of XBB.1.5 related to strong ACE2 binding and antibody evasion [here](#)
- Increased interleukin-6 is associated with long COVID: a systematic review [here](#)
- Left ventricular function and myopericarditis after mRNA COVID-19 vaccination [here](#)
- Anti-coagulation therapy reduced mortality in COVID-19 patients with high cardiovascular risk [here](#)
- Effectiveness of the bivalent mRNA vaccine in preventing severe COVID-19 outcomes [here](#)
- Bivalent mRNA vaccine improves antibody-mediated neutralisation of many Omicron variants [here](#)
- Effectiveness of infection and vaccines against BA.4/BA.5 and XBB in Singapore [here](#)
- Prior infection- and/or vaccine-induced protection against Omicron BA.1, BA.2 and BA.4/BA.5-related hospitalisations in older adults [here](#)
- Humoral responses against BQ.1.1 after breakthrough infection and mRNA vaccination [here](#)
- Clinical characteristics and outcomes from Omicron subvariants and XBB recombinant variant [here](#)
- Poor neutralising antibody responses against Omicron BQ.1.1 and XBB [here](#)
- Sotrovimab and COVID-19-related hospitalisations or deaths among U.S. veterans [here](#)

- Impact of congenital heart disease on paediatric patients hospitalised for COVID-19 infection [here](#)
- Modelling of Omicron variant outbreaks after easing zero-COVID strategy in China [here](#)

Guidance and reports

- World Health Organization published:
 - XBB.1.5 rapid risk assessment, 11 January 2023 [here](#)
 - Technical Advisory Group on Virus Evolution on the COVID-19 situation in China [here](#)
 - Weekly epidemiological update on COVID-19 [here](#)
- European Centre for Disease Prevention and Control on the XBB.1.5 sub-lineage [here](#)
- TGA COVID-19 vaccine safety report [here](#)

News and blogs

- Coronavirus variant XBB.1.5 rises in the United States — is it a global threat? [here](#)
- UK deaths from all causes 3.1% above average during the pandemic [here](#)
- Combined COVID-19 and flu test authorised for point-of-care use [here](#)
- COVID drug Paxlovid was hailed as a game-changer. What happened? [here](#)
- Nirmatrelvir associated with lower risk of long COVID [here](#)
- China stops counting cases as models predict a million or more deaths [here](#)
- Doctors are asked to help track variants among people arriving from China [here](#)
- NHS is struggling to treat more patients than before pandemic despite more staff and funding [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).